Pyxis Oncology to Participate in Upcoming Investor Conferences

Core Insights - Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for difficult-to-treat cancers [2] - The company will participate in two upcoming investor conferences in November 2025, including the Guggenheim 2 Annual Healthcare Innovation Conference and the Stifel 2025 Healthcare Conference [1][3] Company Overview - Pyxis Oncology's lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody drug conjugate (ADC) targeting extradomain-B of fibronectin (EDB+FN), which is overexpressed in various solid tumors [2] - MICVO aims to treat solid tumors through a mechanism involving direct tumor cell killing, bystander effect, and immunogenic cell death [2] - The drug is currently in Phase 1 clinical studies for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and other solid tumors, both as a monotherapy and in combination with Merck's KEYTRUDA® [2]